Q32 Bio
Company

Last deal

$42M

Amount

Venture - Series Unknown

Stage

25.03.2024

Date

3

all rounds

$148M

Total amount

date founded

Financing round

General

About Company
Q32 Bio develops biotech treatments for severe autoimmune and inflammatory diseases.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2017

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

The company's team of immunology experts has developed a platform that targets the IL-7 pathway and complement system to restore immune homeostasis in patients with diseases that have few treatment options. Their product pipeline includes a monoclonal antibody antagonist of the IL-7 receptor and fusion proteins to downregulate complement activity in affected tissues. Q32 Bio aims to help patients take back control of their lives by addressing dysregulation in the immune system.
Contacts

Contact Email

Social url

Similar Companies
1000
Heat Biologics

Heat Biologics

Heat Biologics is a biopharmaceutical company focused on developing therapies to modulate the immune system.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Chapel Hill, NC, USA

total rounds

8

total raised

$59.33M
REGiMMUNE

REGiMMUNE

REGiMMUNE is a biotech company producing immune-regulatory therapeutics for life-threatening diseases and debilitating disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Tokyo, Japan

total rounds

9

total raised

$51.95M
Orpheus Bioscience

Orpheus Bioscience

Orpheus Bioscience develops novel treatments for autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Manassas, VA, USA
Biond Biologics

Biond Biologics

Biond Biologics is an Israeli biotech company focused on cancer immunotherapy and autoimmune disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Misgav Regional Council, Israel

total rounds

2

total raised

$32M

Financials

Funding Rounds
3
3

Number of Funding Rounds

$148M

Money Raised

Their latest funding was raised on 25.03.2024. Their latest investor Bristol Myers Squibb. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
OrbiMed

OrbiMed

OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Health Care

Location

New York, NY, USA

count Of Investments

561

count Of Exists

82
Acorn Bioventures

Acorn Bioventures

The company invests in and partners with biotech and medical device companies.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Location

New York, NY, USA

count Of Investments

23
Atlas Venture

Atlas Venture

Atlas Venture invests in biotech startups with seed and early stage venture investments.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Venture Capital, Financial Services, Biotechnology

Location

Cambridge, MA, USA

total rounds

1

count Of Investments

444

count Of Exists

146
Co-Investors
Investors
13
1

Number of lead investors

13

Number of investors

Investor 
Lead 
Round 
Partners 
No
Venture - Series Unknown
No
Series B, Venture - Series Unknown
No
Venture - Series Unknown
Bristol Myers Squibb

Bristol Myers Squibb

Bristol-Myers Squibb is a pharmaceuticals and nutritional products company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Pharmaceuticals, Health Care, Manufacturing

Location

New York, NY, USA

total rounds

5

total raised

$23.58B

count Of Investments

77

count Of Exists

1
Atlas Venture

Atlas Venture

Atlas Venture invests in biotech startups with seed and early stage venture investments.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Venture Capital, Financial Services, Biotechnology

Location

Cambridge, MA, USA

total rounds

1

count Of Investments

444

count Of Exists

146
Acorn Bioventures

Acorn Bioventures

The company invests in and partners with biotech and medical device companies.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Location

New York, NY, USA

count Of Investments

23

People

Founders
1
Shelia Violette
Shelia Violette

Shelia Violette

Shelia Violette, co-founder, Chief Scientific Officer, and President of Research of Q32 Bio, is a scientific leader in the field of inflammation, autoimmunity, and fibrosis. In her more than 20 years of industry experience advancing programs from early research to clinical development, Shelia has provided strategic and operational leadership to multi-disciplinary teams of scientists, led several research and early clinical programs, and authored more than 90 manuscripts and patents. Prior to co-founding Q32 Bio, she was an Entrepreneur in Residence at Atlas Venture and is an Adjunct Associate Professor in the Department of Internal Medicine at the Yale School of Medicine. Prior to her role at Atlas, Shelia served in leadership roles in the Immunology Research group at Biogen, joining Stromedix as Vice President of Research and returning to Biogen as Vice President of Research, spearheading the tissue injury and fibrosis therapeutic area. She also has directed research and led therapeutic programs at several biotechnology companies including Repligen and Ariad. She received her Ph.D. in Pharmacology from Yale University.

current job

Q32 Bio
Q32 Bio

organization founded

1

Shelia Violette

Employee Profiles
7
Jason Campagna

Jason Campagna

Chief Medical Officer

Kathryn Golden

Kathryn Golden

Head of Chemistry, Manufacturing, and Controls

Maria Marzilli

Maria Marzilli

Head of Corporate Development

Kelly Fahnoe

Senior scientist

Susan Kalled

Susan Kalled

Vice President of Biology

Shelia Violette

Shelia Violette

Founder, Chief Scientific Officer, and President of Research

Michael Broxson

Michael Broxson

CEO

Activity

Recent News
11
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month